Friday, July 11 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Friday, July 11 10:15am–12:30pm
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Friday, July 11 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Friday, July 11 10:15am–12:30pm
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Thursday, July 10 4:30–6pm
Taking the Dialogue to the Next Level: Facilitating Open Communication About Obesity
Thursday, July 10 3:30–4:15pm
Friday, July 11 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Friday, July 11 10:15am–12:30pm
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Friday, July 11 10:15am–12:30pm
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Thursday, July 10 2:30–3:30pm
Skin Deep: Tackling Everyday Dermatologic Cases in Primary Care
Thursday, July 10 8:30–9:30am
Brain Check: Promoting Brain Health and Detecting Cognitive Impairment
Friday, July 11 1:45–2:45pm
Pharmacology Updates 2025: New Medications Reshaping Primary Care
Thursday, July 10 8:30–9:30am
Brain Check: Promoting Brain Health and Detecting Cognitive Impairment
Thursday, July 10 7:30–8:30am
Thursday, July 10 10:30–11:30am
Thursday, July 10 4:30–6pm
Taking the Dialogue to the Next Level: Facilitating Open Communication About Obesity
Thursday, July 10 11:30am–12:15pm
Breakthroughs in Psychiatry: Emerging Treatments for Common Disorders
Disclosures
The following financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute. Relevant relationships will be disclosed at the start of each presentation.
Financial Disclosures
- Charles E. Argoff, MD, FABPM
- Researcher: AbbVie; Speaker: AbbVie, Lilly, Scilex, Lundbeck, Averitas Pharma, Teva, Impel, Kowa Pharmaceuticals, Nevro; Consultant: Collegium, Scilex, Vertex, Xgene Pharma, Tris, PainScripts, Nevro; Other: Lundbeck and Teva; Stock Holder (publicly traded company): Pfizer and Trevana
- Oscar A. de Leon-Casasola, MD
- Consultant: Merck Pharmaceuticals, Vertex Pharmaceuticals.
- Lisa M. Ferreira, MD, FOMA
- Speaker: Elil Lilly and Novo Nordisk Inc.
- Katherine E. Galluzzi, DO, CMD, FACOFP
- Advisor: Lilly
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Consultant: OptumRx, Premier, Inc.
- Aubrey J. Grant, MD, FACC
- No relevant financial relationships disclosed.
- Avery Lachance, MD, MPH
- Consultant: Guidepoint, J&J, Pfizer; Researcher: Merck, Pfizer; Advisor: TD Cowen
- Vani Potluri, MD
- No relevant financial relationships disclosed
- Philip Schoenfeld, MD, MSEd, MSc
- Speaker: Ironwood Pharmaceuticals, Ardelyx Pharmaceuticals, Phathom Pharmaceuticals, AbbVie Pharmaceuticals; Consultant: Phathom Pharmaceuticals, Ardelyx Pharmaceuticals
- Chrisandra L. Shufelt, MD, MS, FACP, MSCP
- Advisor: Bayer, Novo Nordisk
- Pierre N. Tariot, MD
- Advisor: AbbVie, Athira, Cognition Therapeutics; Consultant: Acadia, Bristol Myers-Squibb, Corium, ImmunoBrain, Janssen, Maplight, Novartis; Speaker: Astellas; Stock Holder (publicly traded company): Eli Lilly, Novo Nordisk
- Charles Vega, MD, FAAFP
- Consultant: Boehringer Ingelheim, and Exact Sciences
- Shirah Vollmer, MD
- No relevant financial relationships disclosed
Other Disclosures
Pamela Kushner, MD, FAAFP (Reviewer): Speaker and Advisor for AstraZeneca, Boehringer Ingelheim, Corcept, GSK, Haleon, and Novo Nordisk; Speaker for Astellas, Bayer, Janssen, Lilly, and Phathom; Advisor for Abbott and Bausch/SALIX
Amy Clouse, MD (Planner for Brain Check: Promoting Brain Health): Speaker for Astellas, Stockholder for Eli Lilly and Novo Nordisk
Anelyssa D’Abreu, MD (Planner for Brain Check: Promoting Brain Health): Independent contractor for Biogen, Cognition Therapeutics, Eli Lilly, and Janssen
Andrew Budson (Planner for Brain Check: Promoting Brain Health): Advisor for Eli Lilly and AbbVie, Contractor for Vox Neuro and Bristol Meyers Squibb
All other non-faculty contributors involved in the moderating, planning, development, editing and review of the content have disclosed no relevant financial relationships.